WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007089476) CHEMOPREVENTION OF ENDOMETRIAL CANCER
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/089476    International Application No.:    PCT/US2007/001749
Publication Date: 09.08.2007 International Filing Date: 23.01.2007
IPC:
A61K 39/00 (2006.01), A61K 39/38 (2006.01)
Applicants: THE BRIGHAM & WOMEN'S HOSPITAL, INC. [US/US]; 75 Francis Street, Boston, MA 02115 (US) (For All Designated States Except US).
MUTTER, George, L. [US/US]; (US) (For US Only).
VISWANATHAN, Akila, N. [US/US]; (US) (For US Only).
ORBO, Anna [NO/NO]; (NO) (For US Only)
Inventors: MUTTER, George, L.; (US).
VISWANATHAN, Akila, N.; (US).
ORBO, Anna; (NO)
Agent: SANZO, Michael, A.; Law Office Of Michael A. Sanzo, 15400 Calhoun Drive, Suite 125, Rockville, MD 20855 (US)
Priority Data:
60/762,515 27.01.2006 US
11/655,895 22.01.2007 US
Title (EN) CHEMOPREVENTION OF ENDOMETRIAL CANCER
(FR) CHIMIOPRÉVENTION DE CANCER DE L'ENDOMÈTRE
Abstract: front page image
(EN)The present invention is directed to intrauterine devices that release progestins or an inflammatory cytokine after placement. These devices can be used to reduce the risk of a woman developing endometrial cancer. The invention is also directed to therapeutic methods in which a sample of uterine cells obtained from a woman is assayed to determine the extent to which PTEN null clones (latent endometrial precancers) are present. In cases where the number of such null clones is high, the woman is administered an intrauterine device that releases either a progestin or an inflammatory cytokine.
(FR)La présente invention concerne un dispositif intra-utérin qui libère des progestines ou une cytokine inflammatoire après placement. Ces dispositifs peuvent être utilisés pour réduire le risque de développement d'un cancer de l'endomètre chez une femme. L'invention concerne aussi des méthodes thérapeutiques par lesquelles un échantillon de cellules utérines obtenu d'une femme est analysé pour déterminer le niveau de présence de clones PTEN nuls (précancers latents de l'endomètre). Au cas où le nombre desdits clones nuls est élevé, la femme reçoit un dispositif intra-utérin qui libère soit une progestine soit une cytokine inflammatoire.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)